Gandarias J M, Casis L, Casis E, Gómez R, Iribar C
Rev Esp Fisiol. 1987 Mar;43(1):77-80.
The peptidic sequence (Sarcosine-1-Isoleucine-8)-Angiotensin II has been demonstrated to be an in vitro specific and competitive antagonist of the Angiotensin II action. The present results show it to be a competitive antagonist also in vivo since pA2 values are similar, always reaches a 100% response on increasing the Angiotensin II dose, and when relating log (DR-1) and log dose of agonist, the slope is very near to one (0.925).
肽序列(肌氨酸-1-异亮氨酸-8)-血管紧张素II已被证明是血管紧张素II作用的体外特异性竞争性拮抗剂。目前的结果表明,它在体内也是一种竞争性拮抗剂,因为其pA2值相似,在增加血管紧张素II剂量时总能达到100%的反应,并且当绘制激动剂的log(DR-1)与log剂量的关系图时,斜率非常接近1(0.925)。